Biotechnology stocks have had their fair share of bumps and bruises after heavy concern surrounding pricing was brought up by several presidential candidates during the first round of debates. However, since then many stocks in this sector have taken a sharp turn in favor of the bulls. In fact, several have seen news releases on new management and even merger deals spark increased attention not only on the companies but also on the industry as a whole. Companies like VBI Vaccines Inc (NASDAQ:VBIV), KaloBios Pharmaceuticals Inc (NASDAQ:KBIO), Anavex Life Sciences Corp. (NASDAQ:AVXL).
VBI Vaccines Inc (NASDAQ:VBIV) is presenting at the LD Micro Conference this week with President and CEO Jeff Baxter as the presenter. Over the more recent weeks of the last 2 months the company has undergone several key changes including a planned merger with SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF). “We believe that our proposed merger with SciVac would bring a commercial vaccine together with unique vaccine development and manufacturing capabilities. We look forward to potentially combining SciVac’s assets and talent to create what we believe will become a leading global vaccine developer,” stated Baxter in a recent corporate announcement.
This planned merger also brings to the table some of the biotech industry’s notable veteran investors including Dr. Phillip Frost. This is from being SciVac’s majority shareholder, at 25% (14% post-merger) through Opko Health Inc. (NYSE:OPK). Furthermore, since hitting lows in October of $2.25, shares of VBI have rebounded by as much as 27% with volume becoming increasingly more consistent over recent weeks.
Amidst much excitement in the market, KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) has been the source both pain and pleasure depending on how the stock was traded during the incredible run it had beginning in November of this year. What began on November 16th was one of the largest stock runs of 2015 based on overall dollar volume and price movement. Following an opening price of $0.442 on the 16th, shares of KaloBios ran to highs of $45.82 days later. This 10,266.5% move caught many traders short as Martin Shkreli acquired 70% of the outstanding shares of the company and subsequently became its CEO.
Shkreli, as well as other investors committed to an equity investment of “at least $3million apart from a $10 million equity financing facility, subject to shareholder approval,” as cited by Zacks Equity Research.
Anavex Life Sciences Corp. (NASDAQ:AVXL) announced earlier this week that it has appointed Ulrigh Elben, PhD as VP of Preclinical Operations to oversee pipeline development and optimization. Earlier in November the company reported positive results from an Alzheimer’s study. The company announced the publication of further data for Anavex 3-71 in the peer reviewed scientific journal Neurodegenerative Diseases. Evidence provided a positive and more “upstream” effect on reducing synaptic loss, amyloid and tau pathologies and neuroinflammation.
Anavex 3-71 is part of Anavex’s pipeline that also includes Anavex 2-73, which targets sigma-1 and muscarinic receptors. Since hitting lows of $3.16 in mid-November, the stock has seen a rebound of more than 150% after hitting highs of $8.16 on November 30th. The stock currently has held a price between $5.57-$7.08 since hitting those highs.
About Biotech Stocks (www.BiotechStocks.com)
Biotech Stocks (www.biotechstocks.com) is your best resource for today’s emerging biotech industry. Whether you’re looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. BiotechStocks.com, is not registered with any fvb inancial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. BiotechStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. BiotechStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. MAPH Enterprises LLC BiotechStocks.com | was paid an advertising fee of $30,000 cash & ZERO shares by the issuer for visual sponsorship on BiotechStocks.com and for visual placement of VBIV. within written materials. FOR A DURATION OF 30 DAYS BEGINNING 11/30/2015 – 1/1/2016.
Eanings Review: Rambus Inc. (NASDAQ:RMBS), Revlon Inc (NYSE:REV)
Revlon Inc(NYSE:REV) +2.5% after-hours after announcing that President and CEO Fabian Garcia is stepping down “to pursue other opportunities,” and Executive Vice Chair Paul Meister will oversee operations on an interim basis.
REV also says it expects Q4 revenues of $785M, below $801M from the year-earlier quarter but ahead of analyst consensus estimate of $743M, and a $60M-$80M net loss for the quarter due to a charge related to the recent tax law changes.
REV expects Q4 adjusted EBITDA of $110M-$115M vs. $115M analyst consensus.
CFO Chris Peterson also denies rumors that the company is considering a material asset transfer that would shield assets from lenders.
Rambus Inc.(NASDAQ:RMBS) shares are down 5.5% aftermarket following Q4 results that beat revenue estimates and met on EPS. In-line Q1 guidance (under ASC 605 accounting change) has revenue from $94M to $100M (consensus: $100.38M) and EPS from $0.17 to $0.23 (consensus: $0.18).
Revenue breakdown: Royalties, $77.9M (+10% Y/Y); Product, $8.5M (-27%); Contract and other revenue, $15.5M (+2%); Licensing billings, $76.6M (+18%).Key metrics: Non-GAAP operating margin, 31%; total operating expenses, $67.5M; cash and equivalents, $172.2M; cash flow from operations, $33.3M.
ADTRAN, Inc. (NASDAQ:ADTN) Hits New Lows After Issuing disappointing Earnings Forecast
ADTRAN, Inc.(NASDAQ:ADTN) slumped to a 52-week low after forecasting below consensus guidance for Q4, revising its revenue estimate downward to $125M from $155M-$165M earlier and seeing EPS of ~$0.01; analysts had expected EPS of ~$0.14 and revenue of $161.2M.
ADTN also projects Q1 to come in at roughly the same as Q4, misses analyst consensus of $167.5M.
CEO Tom Stanton says Q4 results have been hurt by a merger-related review, which ADTN expects to be completed in 60-90 days, and slowdown in the spending at a domestic Tier 1 customer.
MKM Partners analyst Michael Genovese believes the customer is CenturyLink (CTL -2%), which accounted for 24% of ADTN’s total sales in 2016.
The analyst thinks the weakness should prove temporary, adding that ADTN’s performance likely will accelerate into 2019 as the company stands to benefit from 5G spending; MKM trims its ADTN target price to $25 from $27 but keeps its Buy rating.
Big IPO Coming: Celator Pharmaceuticals Inc(NASDAQ:CPXX), Moleculin Biotech’s (MBRX)
Today at 10am Eastern, Moleculin Biotech ticker symbol MBRX will debut on the Nasdaq stock exchange and is being considered as one of the most highly anticipated IPO’s of 2016 by the street. The excitement and anticipation is arising from many experts saying that Moleculin Biotech’s (MBRX) drug annamycin is far superior to Celator Pharmaceuticals Inc(NASDAQ:CPXX) drug daunorubicin.
CPXX which has been bought out by Jazz Pharmaceuticals plc – Ordinary Shares(NASDAQ:JAZZ) for $1.5 Billion Dollars last week, share price ran from $1.6 to $31 in 2 months. Moleculin Biotech’s share structure is a 1.5m public float Priced at $6.